Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
12/5/23 Merck KGaA (MKKGY) Evobrutinib for Multiple Sclerosis (MS) Subscribers Only Subscribers Only Subscribers Only
12/5/23 Roche (RHHBY) Inavolisib for HR+/HER2- Breast Cancer Subscribers Only Subscribers Only Subscribers Only
12/4/23 Alto Neuroscience ALTO-300 for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only
12/1/23 Pfizer (PFE) Danuglipron for Obesity Subscribers Only Subscribers Only Subscribers Only
11/30/23 CG Oncology CG0070 for Bladder Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
12/08/23 Subscribers Only Subscribers Only Trial Data - Final Results
12/08/23 Subscribers Only Subscribers Only Trial Data - Updated Results
12/08/23 Subscribers Only Subscribers Only Trial Data - Other
12/08/23 Subscribers Only Subscribers Only Trial Data - Updated Results
Now - 12/09/23 Subscribers Only Subscribers Only Trial Data - Other
Back to the top Back to the top